RecruitingNCT00843375

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas


Sponsor

University of Michigan Rogel Cancer Center

Enrollment

1,200 participants

Start Date

Aug 7, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether stool (poop) samples can detect early signs of colorectal cancer or precancerous polyps, by comparing special stool markers against colonoscopy results. **You may be eligible if...** - You are at least 18 years old - You are willing to provide 1–2 stool samples and a stool blood test (FIT) - You fall into one of these groups: you have colorectal cancer not yet treated, you have precancerous polyps (adenomas), you have a personal or family history of colon cancer or polyps, or you are at average risk with no history of colon problems - Pregnant or nursing women may participate if they otherwise qualify **You may NOT be eligible if...** - You have had surgery, radiation, or chemotherapy for your current colorectal cancer before providing samples - You have active inflammatory bowel disease (Crohn's or ulcerative colitis) - You have hereditary colon cancer syndromes (HNPCC or FAP) - You are unable to give informed consent - You have another active cancer (diagnosed within the past 3 years) - You are on active chemotherapy or radiation for any condition - You have HIV or chronic active hepatitis - You are pregnant - You are having a virtual colonoscopy (CT colonography) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(13)

Cedars-Sinai Medical Center

Los Angeles, California, United States

Carle Cancer Center

Urbana, Illinois, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

University of Minnesota

Minneapolis, Minnesota, United States

NYU Langone Health

New York, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Oregon Health and Science University

Portland, Oregon, United States

Hershey Medical Center

Hershey, Pennsylvania, United States

M.D. Anderson Cancer Center

Houston, Texas, United States

University of Washington

Seattle, Washington, United States

Flinders Medical Center

Adelaide, South Australia, Australia

St. Michael's Hospital

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00843375


Related Trials